Company news

BioXcel Therapeutics, Inc. news in 2023

BioXcel Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

December 11, 2023

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

December 10, 2023

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

November 29, 2023

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

November 13, 2023

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

November 7, 2023

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

November 5, 2023

BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023

October 30, 2023

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

October 29, 2023

BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

October 24, 2023

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

October 9, 2023

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

October 3, 2023

BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

August 13, 2023

BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023

July 30, 2023

BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation

June 28, 2023

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

May 31, 2023

BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia

May 24, 2023

BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program

May 15, 2023

BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights

May 7, 2023

BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference

May 1, 2023

BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023

April 23, 2023

OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

March 13, 2023

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

March 8, 2023

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

February 22, 2023

BioXcel Therapeutics to Ring Nasdaq Stock Market Closing Bell Today

February 20, 2023

BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium

February 12, 2023

BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer

February 7, 2023

BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer

January 10, 2023

Calls in 2023

Decks in 2023